Indiana § 16-42-23-6 Regulation of use, sale, prescription, manufacture, or distribution
within state

Indiana Statutes

§ 16-42-23-6 — Regulation of use, sale, prescription, manufacture, or distribution within state

Indiana § 16-42-23-6

Title 16HEALTH

Art. 42REGULATION OF FOOD, DRUGS, AND

Ch. 23Drugs: Use of Amygdalin (Laetrile)

This text of Indiana § 16-42-23-6 (Regulation of use, sale, prescription, manufacture, or distribution within state) is published on Counsel Stack Legal Research, covering Indiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Ind. Code § 16-42-23-6 (2026).

Text

(a)Amygdalin (laetrile) is not a drug or a controlled substance under Indiana statutes governing the use, manufacture, or distribution of drugs and controlled substances within Indiana.

(b)A physician may prescribe amygdalin (laetrile) under this chapter as a treatment that may be prescribed under IC 25-22.5-1-1.1(f).

(c)The state department and the Indiana board of pharmacy may regulate the manufacture, distribution, and sale of amygdalin (laetrile) for use within Indiana only to ensure that the substance is not adulterated or misbranded within the meaning of IC 16-42-3.

(d)The state department may not adopt a rule that prohibits the use of amygdalin (laetrile) in a hospital, an ambulatory outpatient surgical center, or a health care facility licensed by the state department.

(e)The

Free access — add to your briefcase to read the full text and ask questions with AI

(a) Amygdalin (laetrile) is not a drug or a
controlled substance under Indiana statutes governing the use,
manufacture, or distribution of drugs and controlled substances within
Indiana.
(b) A physician may prescribe amygdalin (laetrile) under this
chapter as a treatment that may be prescribed under IC 25-22.5-1-1.1(f).
(c) The state department and the Indiana board of pharmacy may
regulate the manufacture, distribution, and sale of amygdalin (laetrile)
for use within Indiana only to ensure that the substance is not
adulterated or misbranded within the meaning of IC 16-42-3.
(d) The state department may not adopt a rule that prohibits the use
of amygdalin (laetrile) in a hospital, an ambulatory outpatient surgical
center, or a health care facility licensed by the state department.
(e) The Indiana board of pharmacy may not adopt a rule that
prohibits the manufacture, distribution, or sale of amygdalin (laetrile)
by a person or in any place licensed by the Indiana board of pharmacy.
[Pre-1993 Recodification Citation: 16-8-8-6.]